Evidence map›Paper›PMID 40606632›Full record

ArticleFrontiers in cellular and infection microbiology2025

Overweight and

Xu Chen, Jiayue Fu, Kejia Jin, Zixuan Yang, Yidan Qian, Kehan Mei, Yihan Wang, Jialei Min, Yilin Du, Zaisheng Zhu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Safety of high-dose dual therapy forFrontiers in pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xu Chen *Department of Medical Care Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jiayue Fu *School of Information and Engineering, Wenzhou Medical University, Wenzhou, China.
Kejia JinOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Zixuan YangOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Yidan QianOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Kehan MeiSchool of Information and Engineering, Wenzhou Medical University, Wenzhou, China.
Yihan WangSchool of Information and Engineering, Wenzhou Medical University, Wenzhou, China.
Jialei MinSchool of Information and Engineering, Wenzhou Medical University, Wenzhou, China.
Yilin DuSchool of Information and Engineering, Wenzhou Medical University, Wenzhou, China.
Zaisheng ZhuDepartment of Medical Care Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shengcun LiOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) has recently replaced nonalcoholic fatty liver disease (NAFLD) as a term that more accurately describes its pathogenesis. Methods: A retrospective cross-sectional study was conducted, encompassing 5619 participants from the First Affiliated Hospital of Wenzhou Medical University, spanning from April 2016 to August 2017. Detection of Results: No significant correlation between Conclusion: Overweight individuals with MAFLD have a higher prevalence of

Indexed as

Fatty LiverHelicobacter InfectionsHelicobacter pyloriNon-alcoholic Fatty Liver DiseaseOverweightAdultAgedBreath TestsChinaCross-Sectional StudiesFemaleHumansMaleMiddle AgedRetrospective Studiesbody mass index (BMI)Helicobacter pylori (H. pylori)leanmetabolic dysfunction-associated fatty liver disease (MAFLD)overweight

Identifiers

PMID40606632
PMCPMC12213829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.